Seres Therapeutics, Inc. 8-K

What Happened

• On March 12, 2026 Seres Therapeutics, Inc. (NASDAQ: MCRB) announced its financial results for the quarter and year ended December 31, 2025 and provided operational updates. The company issued a press release (furnished as Exhibit 99.1) and posted an updated corporate slide presentation in the "Investors and News" section of its website (furnished as Exhibit 99.2).

Key Details

• Filing date: March 12, 2026 (Current Report on Form 8-K).
• Reporting period: quarter and year ended December 31, 2025.
• Materials furnished: Press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2); slide deck posted at www.serestherapeutics.com under Investors and News.
• Regulatory note: Information in Items 2.02 and 7.01 and Exhibits 99.1/99.2 are furnished (not “filed”) and are not subject to Section 18 liability or incorporation by reference except as expressly stated.

Why It Matters

• The 8-K signals Seres has released its latest quarterly and full‑year financial results and updated guidance/operational context for investors; the press release and slide deck are the primary sources for detailed metrics (revenue, expenses, cash position, program updates).
• Retail investors should review the furnished press release and presentation for the specific financial figures and program milestones, and watch for any subsequently filed reports (e.g., 10‑K or 10‑Q) that formally present audited results and management discussion.